Although it was the COVID-19 pandemic that pushed decentralized clinical trials (DCTs) to the forefront, they had been around for nearly a decade. And while DCTs may increase access to and diversity in clinical trials, study sponsors must ensure participants are safe and protected, while maintaining data integrity.
When you hear DCT, you automatically think it’s going to be more convenient.